The human hypoxia-inducible factor 1alpha gene in anthracycline-induced heart failure

Objective: The objective of the study was to evaluate the role of hypoxia-inducible factor 1alpha (HIF1A) gene (1772C>T, rs11549465) in the course of anthracycline-induced heart failure (AIHF) in women without previous cardiovascular diseases (CVD) during 24 months. Methods: A total of 114 women, median age of 47.0 (44.0; 52.0) years with AIHF of NYHA class I-III who received doxorubicin for breast cancer were enrolled. Evaluation of gene polymorphisms was carried out by polymerase chain reaction at baseline. Results: After 24 months of follow-up all patients had breast cancer remission and were divided into 2 groups: group 1 comprised women with adverse course of AIHF (n = 36), group 2 comprised those without it (n = 75). The presence of C/T genotype of HIF1A gene (1772C>T, rs11549465) (OR = 3.65; p = 0.009) was related with adverse course of AIHF. Women with C/T genotype of HIF1A gene (1772C>T, rs11549465) had further progression of AIHF: left ventricle ejection fraction significantly (p <0.001) decreased by 11.8% from 51 (47; 53) to 45 (43; 46)%, end-systolic dimension increased by 7.8% (p <0.001), and end-diastolic dimension by 5.2% (p <0.001). Conclusion: Polymorphism of C/T of hypoxia-inducible factor 1alpha gene (1772C>T, rs11549465) in women without previous CVD was associated with adverse course of AIHF during 24 months.